CymaBay Entered into a Collaboration and License Agreement with Kaken to Develop and Commercialize Seladelpar for Primary Biliary Cholangitis in Japan
Shots:
- CymaBay will receive ~$34.0M up front & is eligible to receive an additional ~$128.4M upon the achievement of regulatory and sales milestones along with 20+% royalties
- Under the terms of the agreement, Kaken gets an exclusive license to develop, commercialize and market CymaBay’s seladelpar in Japan for PBC. Additionally, the collaboration focuses to improve the lives of patients with cholestatic liver disease in Japan
- Seladelpar could be widely accessible to Japanese patients if it is approved, enhancing CymaBay's efforts to expand access in the US and ROW
Ref: Globenewswire | Image: CymaBay
Related News:- Almirall and Kaken Enter into a License Agreement for the Development and Commercialization of Efinaconazole in Europe
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
